8189 Stock Overview
Engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Tianjin TEDA Biomedical Engineering Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.22 |
| 52 Week High | HK$0.26 |
| 52 Week Low | HK$0.065 |
| Beta | 0.41 |
| 11 Month Change | 13.33% |
| 3 Month Change | 52.41% |
| 1 Year Change | 145.56% |
| 33 Year Change | -11.25% |
| 5 Year Change | 70.00% |
| Change since IPO | -63.17% |
Recent News & Updates
There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 73% Price Jump
Oct 17
There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 38% Price Jump
Aug 16Recent updates
There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 73% Price Jump
Oct 17There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 38% Price Jump
Aug 16Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) 26% Share Price Plunge Could Signal Some Risk
May 07Is Tianjin TEDA Biomedical Engineering (HKG:8189) Weighed On By Its Debt Load?
Sep 12Investors Give Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Shares A 28% Hiding
Apr 17Is Tianjin TEDA Biomedical Engineering (HKG:8189) A Risky Investment?
Apr 07Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?
Nov 01Tianjin TEDA Biomedical Engineering (HKG:8189) Is Making Moderate Use Of Debt
Apr 21Is Tianjin TEDA Biomedical Engineering (HKG:8189) Using Too Much Debt?
Oct 26Tianjin TEDA Biomedical Engineering (HKG:8189) Has Debt But No Earnings; Should You Worry?
Apr 06Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?
Dec 22
Shareholder Returns
| 8189 | HK Chemicals | HK Market | |
|---|---|---|---|
| 7D | -3.9% | -4.8% | -5.3% |
| 1Y | 145.6% | 9.6% | 11.3% |
Return vs Industry: 8189 exceeded the Hong Kong Chemicals industry which returned 9.6% over the past year.
Return vs Market: 8189 exceeded the Hong Kong Market which returned 11.3% over the past year.
Price Volatility
| 8189 volatility | |
|---|---|
| 8189 Average Weekly Movement | 29.7% |
| Chemicals Industry Average Movement | 7.2% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 19.1% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 8189's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 8189's weekly volatility has increased from 17% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 264 | Li Sun | bioteda.com |
Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People’s Republic of China. The company operates through two segments, Biological Compound Fertilisers Products, and Elderly Care and Health Care Services. Its biological compound fertilizer products include active fertilizer, mixture with nitrogen, phosphorus, and potassium with various formulas that are used for the facilitation of balanced growth of grains, fruits, and vegetables.
Tianjin TEDA Biomedical Engineering Company Limited Fundamentals Summary
| 8189 fundamental statistics | |
|---|---|
| Market cap | HK$414.90m |
| Earnings (TTM) | -HK$8.00m |
| Revenue (TTM) | HK$456.23m |
0.9x
P/S Ratio-52.3x
P/E RatioIs 8189 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8189 income statement (TTM) | |
|---|---|
| Revenue | CN¥423.65m |
| Cost of Revenue | CN¥397.02m |
| Gross Profit | CN¥26.63m |
| Other Expenses | CN¥34.06m |
| Earnings | -CN¥7.43m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0039 |
| Gross Margin | 6.29% |
| Net Profit Margin | -1.75% |
| Debt/Equity Ratio | 167.1% |
How did 8189 perform over the long term?
See historical performance and comparison